Stock Market Reviews

SCNX (Scienture Holdings, Inc.) News

Get the latest news, insights, and market updates on SCNX (Scienture Holdings, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Scienture Secures Rebate Deal to Promote Stroke and Diabetes Drug Adoption
  Scienture Holdings (SCNX) said Tuesday it has formalized a commercial Pharmacy Benefit Manager led G
  Sep 16, 2025 - $SCNX
• SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
  Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life COMMACK, NY, Sept. 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel
  Sep 16, 2025 - $SCNX
• EXCLUSIVE: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market
  Scienture Holdings, Inc. (NASDAQ:SCNX) on Tuesday announced that it has formalized a commercial Pharmacy Benefit Manager (PBM) led Group Purchasing Organization (GPO) rebate agreement, advancing the process of securing formulary access with health plans covering more than 100 million lives for Arbli (losartan potassium) Oral Suspension, 10 mg/mL. Additional discussions are underway to expand both commercial and government coverage for the product. Arbli is FDA-approved for the treatment of hyper
  Sep 16, 2025 - $SCNX
• Scienture Holdings Second Quarter 2025 Earnings: US$0.47 loss per share (vs US$1.16 loss in 2Q 2024)
  NasdaqCM:SCNX 1 Year Share Price vs Fair Value Explore Scienture Holdings's Fair Values from the Community and select...
  Aug 15, 2025 - $SCNX
• Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock
  Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (Nasdaq: SCNX) (“Scienture” or the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has entered into a securities purchase agreement with certain institutional investors to pu
  Aug 14, 2025 - $SCNX
• SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.
  COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the shipment of launch quantities of Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL to its 3PL/Distribution Center fo
  Aug 13, 2025 - $SCNX
• Scienture Holdings: Q2 Earnings Snapshot
  TAMPA, Fla. AP) — Scienture Holdings, Inc. SCNX) on Tuesday reported a loss of $6.7 million in its second quarter.
  Aug 12, 2025 - $SCNX
• Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding
  Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its board of directors has approved a bridge funding raise of up to an aggregate amount of $3 million, of whic
  Jul 24, 2025 - $SCNX